BeOne Medicines Ltd. (ONC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 2.5B 5B 7.5B Q3 '16: 5.7M Q4 '16: 1.1M Q1 '17: 393K Q2 '17: 0 Q3 '17: 220.2M Q4 '17: 238.4M Q1 '18: 270.9M Q2 '18: 323.7M Q3 '18: 157.7M Q4 '18: 198.2M Q1 '19: 243.5M Q2 '19: 434.1M Q3 '19: 430M Q4 '19: 428.2M Q1 '20: 402.4M Q2 '20: 224.7M Q3 '20: 265.7M Q4 '20: 308.9M Q1 '21: 862.7M Q2 '21: 947M Q3 '21: 1.1B Q4 '21: 1.2B Q1 '22: 877M Q2 '22: 1.1B Q3 '22: 1.2B Q4 '22: 1.4B Q1 '23: 1.6B Q2 '23: 1.8B Q3 '23: 2.2B Q4 '23: 2.5B Q1 '24: 2.8B Q2 '24: 3.1B Q3 '24: 3.3B Q4 '24: 3.8B Q1 '25: 4.2B Q2 '25: 4.6B Q3 '25: 5B Q4 '25: 5.3B Q1 '26: 5.7B Q2 '26: 6.1B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 2B 4B 6B Q4 '23: 2.1B Q1 '24: 2.3B Q2 '24: 2.6B Q3 '24: 2.8B Q4 '24: 3.2B Q1 '25: 3.5B Q2 '25: 3.9B Q3 '25: 4.3B Q4 '25: 4.7B Q1 '26: 5.1B Q2 '26: 5.4B Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income TTM

-2.1B -1.4B -700M 0 700M 1.4B 2.1B Q3 '16: -106.2M Q4 '16: -117.1M Q1 '17: -148.3M Q2 '17: -181.7M Q3 '17: -31.9M Q4 '17: -98.5M Q1 '18: -157.7M Q2 '18: -262.8M Q3 '18: -528.8M Q4 '18: -705.8M Q1 '19: -768.7M Q2 '19: -691.5M Q3 '19: -852.7M Q4 '19: -959.9M Q1 '20: -1.2B Q2 '20: -1.4B Q3 '20: -1.6B Q4 '20: -1.7B Q1 '21: -1.2B Q2 '21: -1.3B Q3 '21: -1.4B Q4 '21: -1.4B Q1 '22: -2B Q2 '22: -1.9B Q3 '22: -1.9B Q4 '22: -1.8B Q1 '23: -1.7B Q2 '23: -1.6B Q3 '23: -1.3B Q4 '23: -1.2B Q1 '24: -1.1B Q2 '24: -886.3M Q3 '24: -872.6M Q4 '24: -568.2M Q1 '25: -295.7M Q2 '25: -100.7M Q3 '25: 182.7M Q4 '25: 447.1M Q1 '26: 685.9M Q2 '26: 923.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-2.4B -1.6B -800M 0 800M 1.6B 2.4B Q3 '16: -108.9M Q4 '16: -119.2M Q1 '17: -147.8M Q2 '17: -184.3M Q3 '17: -31.4M Q4 '17: -93.1M Q1 '18: -147.1M Q2 '18: -243.4M Q3 '18: -504.8M Q4 '18: -673.8M Q1 '19: -736.8M Q2 '19: -665.5M Q3 '19: -828.8M Q4 '19: -948.6M Q1 '20: -1.1B Q2 '20: -1.4B Q3 '20: -1.5B Q4 '20: -1.6B Q1 '21: -1.2B Q2 '21: -1.3B Q3 '21: -1.3B Q4 '21: -1.4B Q1 '22: -1.9B Q2 '22: -2B Q3 '22: -2.1B Q4 '22: -2B Q1 '23: -1.9B Q2 '23: -1.7B Q3 '23: -959.5M Q4 '23: -881.7M Q1 '24: -784.4M Q2 '24: -523.7M Q3 '24: -860.5M Q4 '24: -644.8M Q1 '25: -392.4M Q2 '25: -177.6M Q3 '25: 68.5M Q4 '25: 286.9M Q1 '26: 513M Q2 '26: 655.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 150M 300M 450M Q2 '18: 15.8M Q3 '18: 22.5M Q4 '18: 28.7M Q1 '19: 39.4M Q2 '19: 51M Q3 '19: 62.4M Q4 '19: 71.2M Q1 '20: 70.1M Q2 '20: 66.5M Q3 '20: 67.6M Q4 '20: 70.7M Q1 '21: 89.2M Q2 '21: 111.1M Q3 '21: 137.4M Q4 '21: 164.9M Q1 '22: 197.5M Q2 '22: 232.4M Q3 '22: 261.5M Q4 '22: 286.5M Q1 '23: 303M Q2 '23: 327.8M Q3 '23: 347.6M Q2 '18 Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Operating Cash Flow TTM

-2.1B -1.4B -700M 0 700M 1.4B 2.1B Q3 '16: -80.1M Q4 '16: -89.5M Q1 '17: -105.4M Q2 '17: -138M Q3 '17: -107.1M Q4 '17: 12.8M Q1 '18: -56M Q2 '18: -121.3M Q3 '18: -260.1M Q4 '18: -547.7M Q1 '19: -615.2M Q2 '19: -544.2M Q3 '19: -677M Q4 '19: -750.3M Q1 '20: -920.2M Q2 '20: -1.1B Q3 '20: -1.2B Q4 '20: -1.3B Q1 '21: -816.4M Q2 '21: -973.7M Q3 '21: -1.1B Q4 '21: -1.3B Q1 '22: -1.7B Q2 '22: -1.6B Q3 '22: -1.7B Q4 '22: -1.5B Q1 '23: -1.8B Q2 '23: -1.7B Q3 '23: -1.3B Q4 '23: -1.2B Q1 '24: -902.2M Q2 '24: -703.9M Q3 '24: -437.4M Q4 '24: -140.6M Q1 '25: 212M Q2 '25: 571.2M Q3 '25: 785.4M Q4 '25: 1.1B Q1 '26: 1.3B Q2 '26: 1.5B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-2.4B -1.6B -800M 0 800M 1.6B 2.4B Q3 '16: -99M Q4 '16: -113M Q1 '17: -130.7M Q2 '17: -161.6M Q3 '17: -142.6M Q4 '17: -33.6M Q1 '18: -107M Q2 '18: -179.1M Q3 '18: -326M Q4 '18: -618M Q1 '19: -697.6M Q2 '19: -637.4M Q3 '19: -774.4M Q4 '19: -839.9M Q1 '20: -1B Q2 '20: -1.2B Q3 '20: -1.3B Q4 '20: -1.4B Q1 '21: -954.8M Q2 '21: -1.1B Q3 '21: -1.3B Q4 '21: -1.6B Q1 '22: -1.9B Q2 '22: -1.9B Q3 '22: -2B Q4 '22: -1.8B Q1 '23: -2.2B Q2 '23: -2.2B Q3 '23: -1.8B Q4 '23: -1.7B Q1 '24: -1.5B Q2 '24: -1.3B Q3 '24: -994.6M Q4 '24: -633.3M Q1 '25: -180.5M Q2 '25: 244.8M Q3 '25: 544.6M Q4 '25: 941.7M Q1 '26: 1.1B Q2 '26: 1.3B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q3 '16: 428.1M Q3 '17: 600.6M Q3 '18: 739.8M Q1 '20: 1B Q2 '20: 1B Q3 '20: 1.1B Q1 '21: 1.3B Q2 '21: 1.2B Q3 '21: 1.2B Q1 '22: 1.3B Q2 '22: 1.3B Q3 '22: 1.3B Q1 '23: 1.4B Q2 '23: 1.4B Q3 '23: 1.4B Q1 '24: 1.4B Q2 '24: 1.4B Q3 '24: 1.4B Q1 '25: 1.4B Q2 '25: 1.5B Q3 '25: 1.5B Q1 '26: 1.5B Q2 '26: 1.5B Q3 '17 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.80 -1.20 -0.60 0.00 0.60 1.20 1.80 Q3 '16: -0.44 Q4 '16: -0.29 Q1 '17: -0.32 Q2 '17: -0.38 Q3 '17: -0.10 Q4 '17: -0.19 Q1 '18: -0.25 Q2 '18: -0.35 Q3 '18: -0.74 Q4 '18: -0.92 Q1 '19: -0.98 Q2 '19: -0.87 Q3 '19: -1.07 Q4 '19: -1.21 Q1 '20: -1.35 Q2 '20: -1.57 Q3 '20: -1.55 Q4 '20: -1.46 Q1 '21: -1.05 Q2 '21: -1.12 Q3 '21: -1.11 Q4 '21: -1.20 Q1 '22: -1.58 Q2 '22: -1.60 Q3 '22: -1.65 Q4 '22: -1.49 Q1 '23: -1.42 Q2 '23: -1.28 Q3 '23: -0.72 Q4 '23: -0.66 Q1 '24: -0.59 Q2 '24: -0.40 Q3 '24: -0.64 Q4 '24: -0.48 Q1 '25: -0.29 Q2 '25: -0.14 Q3 '25: 0.03 Q4 '25: 0.18 Q1 '26: 0.33 Q2 '26: 0.43 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.